Senior US District Judge Rebecca Beach Smith has granted approval for a $70 million settlement reached between a class of drug purchasers and pharmaceutical giants Merck and Glenmark Pharmaceuticals. This settlement arises from allegations of collusion between the two companies to delay the release of a generic version of Merck’s popular anti-cholesterol drug, Zetia, reported Reuters.
Judge Smith delivered her ruling on Wednesday, affirming that the settlement was “fair, reasonable, and adequate.” This decision allows the plaintiffs, which encompass various municipal employee benefit funds, to mitigate the risks associated with a protracted trial. The court’s approval effectively concludes a five-year antitrust litigation saga centered around Merck’s Zetia.
Read more: Merck, Glenmark Must Face Antitrust Trial Over Drug Pricing
Additionally, Judge Smith has endorsed a request made by the plaintiffs’ legal representatives, which include Motley Rice and Miller Law, for a total of $23.3 million in fees. This amount represents one-third of the overall settlement, coupled with $3.9 million in costs. The judge determined that this request was not excessive and aligned with precedents from comparable cases within the pharmaceutical industry.
As of now, there has been no immediate response from Merck, Glenmark, or the plaintiffs’ legal representatives regarding this development.
The initial complaint, filed by the plaintiffs in 2018, alleged that both Merck and Glenmark violated antitrust laws as a result of a 2010 settlement. This settlement saw Merck relinquishing its patent infringement claims against Glenmark’s proposed generic version of Zetia, with Glenmark agreeing to postpone the release of their generic product for nearly five years.
Source: Reuters
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI